Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q3 Earnings Expected to Decline
02:02pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
10:14am, Thursday, 20'th Oct 2022
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St
Alnylam (ALNY) Soars 3.6%: Is Further Upside Left in the Stock?
12:34pm, Friday, 14'th Oct 2022 Zacks Investment Research
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Alnylam (ALNY) Soars 3.6%: Is Further Upside Left in the Stock?
09:47am, Friday, 14'th Oct 2022
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Where Alnylam Pharmaceuticals Stands With Analysts
02:06pm, Thursday, 13'th Oct 2022 Benzinga
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
6
0
Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company
12:12pm, Thursday, 13'th Oct 2022 Benzinga
Deutsche Bank cut Deere & Company (NYSE: DE) price target from $389 to $365. Deere shares rose 0.5% to $363.00 in pre-market trading.
BTIG cut Roblox Corporation (NYSE: RBLX) price target from $58
3 Top Biotech Stocks Defying the Bear Market
09:52am, Tuesday, 11'th Oct 2022 The Motley Fool
Bear market, shmear market. These biotech stocks are soaring despite the market downturn.
Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion
04:12pm, Friday, 07'th Oct 2022 Zacks Investment Research
The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.
Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion
01:33pm, Friday, 07'th Oct 2022
The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.
Where Alnylam Pharmaceuticals Stands With Analysts
09:02pm, Monday, 03'rd Oct 2022 Benzinga
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with unders
What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
07:20pm, Monday, 03'rd Oct 2022 Benzinga
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
7
0
0
Analyst Ratings for Alnylam Pharmaceuticals
05:14pm, Monday, 03'rd Oct 2022 Benzinga
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
7
0
0
Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More
04:17pm, Thursday, 22'nd Sep 2022 Zacks Investment Research
Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod
10:32pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod
07:33pm, Wednesday, 21'st Sep 2022
The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
